3.81
+0.02(+0.53%)
Currency In USD
| Previous Close | 3.79 |
| Open | 3.78 |
| Day High | 3.87 |
| Day Low | 3.67 |
| 52-Week High | 5.64 |
| 52-Week Low | 2.01 |
| Volume | 990,869 |
| Average Volume | 1.15M |
| Market Cap | 253.46M |
| PE | -4.1 |
| EPS | -0.93 |
| Moving Average 50 Days | 3.01 |
| Moving Average 200 Days | 3.26 |
| Change | 0.02 |
If you invested $1000 in Cardiff Oncology, Inc. (CRDF) 10 years ago, it would be worth $4.25 as of June 14, 2025 at a share price of $3.81. Whereas If you bought $1000 worth of Cardiff Oncology, Inc. (CRDF) shares 5 years ago, it would be worth $1,594.14 as of June 14, 2025 at a share price of $3.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
GlobeNewswire Inc.
Jun 02, 2025 8:05 PM GMT
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclitaxel, and ob
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
GlobeNewswire Inc.
Apr 23, 2025 8:05 PM GMT
The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Apr 15, 2025 8:10 PM GMT
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non